Dato-DXd在晚期非小细胞肺癌中的暴露-反应分析
Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer
作者：Ying Hong、Anna M. Mc Laughlin、Yuzhuo Pan、Sofia Friberg Hietala、Sophie Peigné、Michael Chargualaf、Zoey Tang、Diansong Zhou、Naoyuki Tajima、Malaz Abutarif、Tushar Garimella
单位：Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.；Pharmetheus AB, Uppsala, Sweden.；Clinical Development, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.；Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gaithersburg, Maryland, USA.；Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Boston, Massachusetts, USA.；Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
摘要
Clinical Pharmacology & Therapeutics发表早期在线文章，报道抗体药物偶联物Dato-DXd（TROP2靶向）在晚期非小细胞肺癌患者中的暴露-反应分析结果。该研究为Dato-DXd的临床给药方案优化提供药代动力学/药效学证据支持。
AI 主编 · 推荐理由推荐理由
Dato-DXd是国内药企重点布局的ADC靶点，该暴露-反应数据可辅助理解剂量-疗效/安全性关系，建议关注其IND/NDA申报策略及同类竞品研发进度。